Kinnosuke Matsumoto

Osaka, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 39 publications

EGFR Wild-Type Sarcomatoid Carcinoma as Acquired Resistance to Tarlatamab in Small Cell-Transformed EGFR-Mutated Lung Adenocarcinoma: A Case Report.

EGFR Wild-Type Sarcomatoid Carcinoma as Acquired Resistance to Tarlatamab in Small Cell-Transformed EGFR-Mutated Lung Adenocarcinoma: A Case Report.

Journal: JTO clinical and research reports

Published: July 28, 2026

Impact of preexisting interstitial lung disease on pneumonitis and survival during first-line immune checkpoint inhibitor-based therapy in non-small cell lung cancer.

Impact of preexisting interstitial lung disease on pneumonitis and survival during first-line immune checkpoint inhibitor-based therapy in non-small cell lung cancer.

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 08, 2026

Authors' Reply to Letter to the Editor: Sequential Ramucirumab Plus Docetaxel After PD-1 Inhibitors.

Authors' Reply to Letter to the Editor: Sequential Ramucirumab Plus Docetaxel After PD-1 Inhibitors.

Journal: Cancer science

Published: March 28, 2026

Comparison of Long-Term Survival Between Nivolumab Plus Ipilimumab and Nivolumab Plus Ipilimumab With Chemotherapy in Advanced NSCLC: A Multicenter Retrospective Cohort Study.

Comparison of Long-Term Survival Between Nivolumab Plus Ipilimumab and Nivolumab Plus Ipilimumab With Chemotherapy in Advanced NSCLC: A Multicenter Retrospective Cohort Study.

Journal: JTO clinical and research reports

Published: March 24, 2026

Systemic Inflammation Modifies the Efficacy of Bevacizumab Added to Atezolizumab Plus Chemotherapy for Advanced Non-Squamous Non-Small Cell Lung Cancer: A Multicenter Retrospective Study.

Systemic Inflammation Modifies the Efficacy of Bevacizumab Added to Atezolizumab Plus Chemotherapy for Advanced Non-Squamous Non-Small Cell Lung Cancer: A Multicenter Retrospective Study.

Journal: Thoracic cancer

Published: January 31, 2026

Impact of pre-existing interstitial lung abnormalities on pneumonitis risk and survival in chemo-naive patients with non-small-cell lung cancer receiving pembrolizumab plus chemotherapy.

Impact of pre-existing interstitial lung abnormalities on pneumonitis risk and survival in chemo-naive patients with non-small-cell lung cancer receiving pembrolizumab plus chemotherapy.

Journal: Respiratory medicine

Published: December 24, 2025

Comparison of long-term survival between nivolumab plus ipilimumab with chemotherapy and pembrolizumab with chemotherapy in advanced non-small cell lung cancer: A multicenter retrospective cohort study.

Comparison of long-term survival between nivolumab plus ipilimumab with chemotherapy and pembrolizumab with chemotherapy in advanced non-small cell lung cancer: A multicenter retrospective cohort study.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: December 03, 2025

Impact of Sequential Ramucirumab Plus Docetaxel After PD-1 Inhibitors on Anti-PD-1 Antibody-Bound T-Cell Dynamics and Clinical Outcomes.

Impact of Sequential Ramucirumab Plus Docetaxel After PD-1 Inhibitors on Anti-PD-1 Antibody-Bound T-Cell Dynamics and Clinical Outcomes.

Journal: Cancer science

Published: November 17, 2025

Corrigendum to "Timing of first pembrolizumab infusion and long-term outcomes in non-small cell lung cancer: A retrospective multicenter study" [Eur J Cancer. 2025;228:115748].

Corrigendum to "Timing of first pembrolizumab infusion and long-term outcomes in non-small cell lung cancer: A retrospective multicenter study" [Eur J Cancer. 2025;228:115748].

Journal: European journal of cancer (Oxford, England : 1990)

Published: October 04, 2025

Single-cell spatial analysis identifies ID1-high endothelial cells in tertiary lymphoid structures as predictors of durable response to immunotherapy in non-small cell lung cancer.

Single-cell spatial analysis identifies ID1-high endothelial cells in tertiary lymphoid structures as predictors of durable response to immunotherapy in non-small cell lung cancer.

Journal: Cancer cell international

Published: August 21, 2025

Clinical Outcomes of First-Line Pembrolizumab Monotherapy in Advanced NSCLC With PD-L1 Tumor Proportion Score of 1% to 49%: A Retrospective Multicenter Study.

Clinical Outcomes of First-Line Pembrolizumab Monotherapy in Advanced NSCLC With PD-L1 Tumor Proportion Score of 1% to 49%: A Retrospective Multicenter Study.

Journal: JTO clinical and research reports

Published: August 18, 2025

Long-term survival comparison of first-line pembrolizumab versus pembrolizumab plus chemotherapy for patients with advanced non-small cell lung cancer: A multicenter propensity-matched cohort study.

Long-term survival comparison of first-line pembrolizumab versus pembrolizumab plus chemotherapy for patients with advanced non-small cell lung cancer: A multicenter propensity-matched cohort study.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: August 12, 2025

Showing 1-12 of 39

Last Updated: 09/26/2026